β¨ Medicine Consents
17 AUGUST NEW ZEALAND GAZETTE 2269
Product:
Active Ingredient(s):
Doxorubicin
Dosage Form:
Solution for injection
New Zealand Sponsor:
Hexal New Zealand Pty Limited
Manufacturer(s):
Ebewe Arzneimittel GmbH, Unterach, Austria
Doxorubicin Hexal
Doxorubicin hydrochloride 2mg/mL
Product:
Active Ingredient(s):
Disodium etidronate
Dosage Form:
Tablet
New Zealand Sponsor:
Pacific Pharmaceuticals Limited
Manufacturer(s):
Genpharm Inc., Pharmaceuticals, Etobicoke, Ontario, Canada
Etidrate
Disodium etidronate 200mg
Product:
Active Ingredient(s):
Disodium etidronate
Dosage Form:
Tablet
New Zealand Sponsor:
Pacific Pharmaceuticals Limited
Manufacturer(s):
Genpharm Inc., Pharmaceuticals, Etobicoke, Ontario, Canada
Etidrate
Disodium etidronate 400mg
Product:
Active Ingredient(s):
Alcohol 22.5%v/v
Benzoic acid 0.105%w/v
Cineole 0.092%w/v
Thymol 0.064%w/v
Zinc chloride 0.09%w/v
Dosage Form:
Mouthwash
New Zealand Sponsor:
Warner-Lambert Consumer Healthcare Pty Limited
Manufacturer(s):
Parke Davis Pty Limited, Caringbah, Sydney, New South Wales, Australia
Listerine Tartar Control Antiseptic Mouthwash
Product:
Active Ingredient(s):
Flupenthixol decanoate
Dosage Form:
Injection (depot)
New Zealand Sponsor:
Pacific Pharmaceuticals Limited
Manufacturer(s):
Merck KGaA, Darmstadt, Germany
Psyxitoxol Injection
Flupenthixol decanoate 100mg/mL
Product:
Active Ingredient(s):
Flupenthixol decanoate
Dosage Form:
Injection (depot)
New Zealand Sponsor:
Pacific Pharmaceuticals Limited
Manufacturer(s):
Merck KGaA, Darmstadt, Germany
Psyxitoxol Injection
Flupenthixol decanoate 200mg/mL
Product:
Active Ingredient(s):
Flupenthixol decanoate
Dosage Form:
Injection (depot)
New Zealand Sponsor:
Pacific Pharmaceuticals Limited
Manufacturer(s):
Merck KGaA, Darmstadt, Germany
Psyxitoxol
Flupenthixol decanoate 20mg/mL
Dated this 9th day of August 2000.
G. R. BOYD,
Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go5953
Renewal of Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product:
Hivid
Active Ingredient(s):
Zalcitabine 0.75mg
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Roche Products (New Zealand) Limited
Manufacturer(s):
Hoffmann-La Roche Inc, Nutley, New Jersey, United States of America
Note: This consent is valid for 2 years from 17 December 2000.
Dated this 9th day of August 2000.
G. R. BOYD,
Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go5955
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2000, No 92
Gazette.govt.nz —
NZ Gazette 2000, No 92
β¨ LLM interpretation of page content
π₯ Consent to the Distribution of New Medicines
π₯ Health & Social Welfare9 August 2000
Medicines Act 1981, New Medicine Distribution, Doxorubicin, Etidrate, Listerine, Psyxitoxol
- G. R. Boyd, Chief Advisor, Safety and Regulation
π₯ Renewal of Provisional Consent to the Distribution of a New Medicine
π₯ Health & Social Welfare9 August 2000
Medicines Act 1981, New Medicine Distribution, Hivid, Zalcitabine
- G. R. Boyd, Chief Advisor, Safety and Regulation